Compass Therapeutics Inc.

NASDAQ CMPX

Download Data

Compass Therapeutics Inc. Accounts Payable Turnover Ratio 5 year CAGR for the quarter ending March 31, 2024

Compass Therapeutics Inc. Accounts Payable Turnover Ratio 5 year CAGR is NA for the quarter ending March 31, 2024. The accounts payable turnover ratio measures the number of times a company pays off its accounts payable during a specific period. It is calculated by dividing the company's revenue by its accounts payable. This ratio indicates how efficiently a company manages its outstanding payments to suppliers and vendors. A higher turnover ratio suggests that the company is paying off its obligations quickly, while a lower ratio may indicate a slower payment process or potential liquidity issues. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Compass Therapeutics Inc. Accounts Payable Turnover Ratio for the quarter ending March 31, 2023 was 0.00, a 0.00% change year over year.
  • Compass Therapeutics Inc. Accounts Payable Turnover Ratio for the quarter ending March 31, 2022 was 0.00, a 0.00% change year over year.
  • Compass Therapeutics Inc. Accounts Payable Turnover Ratio for the quarter ending March 31, 2021 was 0.00.
NASDAQ: CMPX

Compass Therapeutics Inc.

CEO Dr. Thomas J. Schuetz M.D., Ph.D.
IPO Date April 5, 2021
Location United States
Headquarters 80 Guest Street, Boston, MA, United States, 02135
Employees 32
Sector Healthcare
Industry Biotechnology
Description

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Similar companies

GLUE

Monte Rosa Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

TYRA

Tyra Biosciences Inc

NA

NA

VIGL

Vigil Neuroscience Inc

NA

NA

PRTC

PureTech Health PLC

NA

NA

AVTE

Aerovate Therapeutics Inc

NA

NA

REPL

Replimune Group Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email